Use of A-STEP Test in Cystic Fibrosis Patients

NCT05809492 | Unknown

• 1 other identifier: MAR.FTR.AD2
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

The exercise test provides prognostic information about clinical outcomes and quality of life to optimize care for cystic fibrosis patients (pwCF). The exercise test identifies the causes of exercise restriction, adverse exercise reactions, and exercise-related symptoms. The results help to determine and evaluate the impact of exercise programs at PWCF. Peak oxygen uptake (VO2peak) is a prognostic measure of maximum exercise capacity that usually worsens as CF lung disease progresses. The recommended gold standard exercise test at PWCF is a cardiopulmonary exercise test (CPET) performed on a loop ergometer to assess VO2peak and cardiopulmonary responses to exercise. the recommended incremental protocol, consisting of 1-minute phases, should reach VO2peak within 8-12 minutes. Trained operators perform cpets with complex and expensive laboratory equipment, and it is inaccessible and little used by many people internationally. Step tests are low-cost, portable, easily standardized and require minimal space to perform. The 3-Minute Step Test (3MST) is an externally paced test for the assessment of exercise tolerance set at 30 steps/minute for 3 minutes. In adults with CF, 3MST is useful for assessing oxygen desaturation and predicting future increased use of healthcare services. Limitations include the ceiling effect in less severe CF lung disease, and it is very difficult for some with more advanced lung disease. An incremental maximum A-STEP step test has been developed to assess exercise capacity in the CF lung disease December, without floor or ceiling effects, within clinical space constraints and the need for strict infection prevention. A-STEP is a new incremental maximum step test to assess exercise capacity in PWCF without floor or ceiling effects, as an alternative field test to CPET.

Conditions

Cystic Fibrosis

Outcome Measures

Primary Outcomes (1)

• Calculation of the maximum exercise capacity using the step test in cystic fibrosis patients

  Calculation of the maximum exercise capacity using the step test in cystic fibrosis patients

  18 minute

Study Arms (3)

Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)< 40%

EXPERIMENTAL

calculation of the maximum exercise capacity using the a-step test

Other: step test

Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)< 40-70%

EXPERIMENTAL

calculation of the maximum exercise capacity using the a-step test

Other: step test

Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)> 70%

EXPERIMENTAL

calculation of the maximum exercise capacity using the a-step test

Other: step test

Interventions

step test OTHER

The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test. the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain. pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely.

Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)< 40%; Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)< 40-70%; Patients with a diagnosis of cystic fibrosis, FEV1(functional expiratory volume)> 70%

Eligibility Criteria

• Age: 10 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• having been diagnosed with cystic fibrosis between the ages of 18 and 50 Dec
• FEV 1 value must be at least 20%
• Being clinically stable (no hospitalization for at least 30 days, no history of acute exacerbations, no changes in maintenance therapy)

You may not qualify if:

• Having evidence of febrile illness
• Hemoptysis
• Uncontrolled asthma
• Pneumothorax
• Cardiac, vascular and renal comorbidities
• Pulmonary hypertension
• CF-related diabetes
• Body mass index \<18 kg/m2
• Pregnancy
• Inability to follow instructions safely

Sponsors & Collaborators

• Marmara University: lead

Study Sites (1)

Mamara Üniversitesi Tıp Fakültesi

Istanbul, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Cystic Fibrosis

Interventions

Exercise Test

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Intervention Hierarchy (Ancestors)

Heart Function Tests; Diagnostic Techniques, Cardiovascular; Diagnostic Techniques and Procedures; Diagnosis; Respiratory Function Tests; Diagnostic Techniques, Respiratory System; Ergometry; Investigative Techniques

Central Study Contacts

Özge Keniş Coşkun, MD

CONTACT

05058294947; Ozgekenis@gmail.com

Burak Yıldız, Dr.

CONTACT

05546797417; adaletli_26@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: patients between the ages of 18-50 with a diagnosis of cystic fibrosis FEV1 \>70%, FEV1 40-70% and FEV1 \<40% who are clinically stable are patients with cystic fibrosis Deciency FEV1 \>70%, FEV1 \<40%.

Study Record Dates

• First Submitted: March 30, 2023
• First Posted: April 12, 2023
• Study Start: January 1, 2023
• Primary Completion: February 1, 2023
• Study Completion: February 1, 2024
• Last Updated: April 12, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)